scholarly journals Demographic trends and KRAS/BRAF V600E mutations in colorectal cancer patients of South China: A single‐site report

2019 ◽  
Author(s):  
Xinhui Fu ◽  
Yan Huang ◽  
Xinjuan Fan ◽  
Yanhong Deng ◽  
Huanliang Liu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
South China ◽  
Single Site ◽  
Braf V600e ◽  
Demographic Trends ◽  
Colorectal Cancer Patients

scholarly journals KRAS and PIK3CA bi-mutations predict a poor prognosis in colorectal cancer patients: A single-site report

2020 ◽  
Vol 13 (12) ◽  
pp. 100874
Author(s):  
Qianxin Luo ◽  
Dianke Chen ◽  
Xinjuan Fan ◽  
Xinhui Fu ◽  
Tenghui Ma ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Poor Prognosis ◽  
Single Site ◽  
Colorectal Cancer Patients

scholarly journals BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Jing Chen ◽  
Fang Guo ◽  
Xin Shi ◽  
Lihua Zhang ◽  
Aifeng Zhang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Kras Codon

scholarly journals Clinicopathological Significance of BRAF V600E Mutation in Egyptian Colorectal Cancer Patients

2020 ◽  
Vol 88 (6) ◽  
pp. 991-997
Author(s):  
MONA A. KORA, M.Sc.; NANSY Y. ASAAD, M.D. ◽  
HALA S. EL-REBEY, M.D.; RANIA A. HASSANIN, M.D. ◽  
ALSHIMAA M. ALHANAFY, M.D.
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Clinicopathological Significance ◽  
Colorectal Cancer Patients

scholarly journals The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation

2019 ◽  
Vol 11 ◽  
pp. 175883591882029 ◽  
Author(s):  
Seiichiro Mitani ◽  
Hiroya Taniguchi ◽  
Keiji Sugiyama ◽  
Toshiki Masuishi ◽  
Kazunori Honda ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Prognostic Score ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Colorectal Cancer Patients ◽  
Line Chemotherapy

Background: BRAF (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival. Recently, clinical trials have been conducted to improve outcomes of second or later lines of chemotherapy. However, there is a paucity of reference data pertaining to outcomes of second-line chemotherapy and prognostic factors that are relevant only to BRAF mutant patients. Patients and methods: We retrospectively reviewed metastatic colorectal cancer patients with BRAF V600E mutation who underwent second-line chemotherapy between January 2007 and March 2017. We evaluated treatment outcomes and performed prognostic analyses. Results: A total of 52 patients were included. The median progression-free survival and overall survival (OS) were 2.5 [95% confidence interval (CI) = 1.91–4.11] and 6.5 (95% CI = 4.30–9.63) months, respectively. Overall response and disease control rates were 7% and 48%, respectively. All the regimens which elicited a partial response included BRAF inhibitors in combination with anti-epidermal growth factor receptor (EGFR) antibodies. Therefore, the overall response was 0% after exclusion of patients treated with study drugs. Multivariate analysis for OS revealed that the Glasgow Prognostic Score (GPS), elevated lactate dehydrogenase, and poor performance status were independent prognostic factors. In particular, survival curves according to the GPS stratified the patients into distinct risk groups. The median OSs in patients with GPS of 0, 1, and 2 were 9.9, 5.0, and 1.9 months, respectively. Conclusions: Outcomes of second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation were extremely poor. GPS may be useful in future clinical trials.

High Frequency of Genes’ Promoter Methylation, but Lack of BRAF V600E Mutation among Iranian Colorectal Cancer Patients

2011 ◽  
Vol 17 (4) ◽  
pp. 819-825 ◽  
Author(s):  
Fakhraddin Naghibalhossaini ◽  
Hamideh Mahmoodzadeh Hosseini ◽  
Pooneh Mokarram ◽  
Mozhdeh Zamani
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Promoter Methylation ◽  
High Frequency ◽  
Braf V600e Mutation ◽  
Braf V600e ◽  
Colorectal Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document